Article
Reference
Liver Imaging and Hepatobiliary Contrast Media
PASTOR, Catherine, LANGER, Oliver, VAN BEERS, Bernard E
PASTOR, Catherine, LANGER, Oliver, VAN BEERS, Bernard E. Liver Imaging and
Hepatobiliary Contrast Media. Contrast Media and Molecular Imaging , 2018, vol. 2018, p.
2487405
DOI : 10.1155/2018/2487405 PMID : 30271310
Available at:
http://archive-ouverte.unige.ch/unige:112681
Disclaimer: layout of this document may differ from the published version.
1 / 1
Editorial
Liver Imaging and Hepatobiliary Contrast Media
Catherine M. Pastor ,
1,2Oliver Langer ,
3and Bernard E. Van Beers
21Department of Radiology, Hˆopitaux Universitaires de Gen`eve, Geneva, Switzerland
2Laboratory of Imaging Biomarkers, Centre of Research on Inflammation, UMR 1149, INSERM, University Paris Diderot, Paris, France
3Austrian Institute of Technology, Vienna, Austria
Correspondence should be addressed to Catherine M. Pastor; catherine.pastor@unige.ch Received 17 July 2018; Accepted 17 July 2018; Published 9 September 2018
Copyright © 2018 Catherine M. Pastor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the past, great achievements have been made by analysing the drug plasma concentrations to understand their body distribution. At that time, the estimation of liver concen- trations was not available. Therefore, when conducting pharmacokinetic studies, it was assumed that hepatocyte concentrations approximate plasma concentrations, with the drug equilibration across the sinusoidal membrane being obtained by passive diffusion. With the discovery of hepa- tocyte transporters that modify the transport rates across hepatocyte membranes, this assumption is no longer valid.
The activity of sinusoidal transporters can be much higher than passive diffusion, increasing the hepatocyte concen- trations over the plasma concentrations. Moreover, the drug concentrations generated by the hepatocyte uptake clear- ances are simultaneously modified by efflux clearances from hepatocytes into bile canaliculi and back into sinusoids.
Thus, depending on the relative hepatocyte influx and efflux clearances, drug hepatocyte concentrations can exceed, equal, or be lower than plasma concentrations. Liver im- aging can now estimate liver concentrations following the injection of hepatobiliary contrast agents and radiotracers.
However, how these concentrations are created is partially unknown. For these reasons, we encouraged the submission of basic, translational, and clinical studies that increase the understanding of liver imaging with hepatobiliary contrast media.
We included six original articles and one review in the special issue. Two publications examined the pharmacoki- netics of Gd-EOB-DTPA and Gd-BOPTA in rat livers.
Myung-Won You and colleagues measure the Gd-EOB-DTPA
vascular clearances in normal rats and rats with hepatectomy (70% and 90%). The serum Gd-EOB-DTPA concentrations identified the decreased uptake function during hepatectomy, and the authors propose this quantification as a new liver function test. A review written by Catherine Pastor shows the value of isolated and perfused rat livers to quantify the Gd- BOPTA distribution into liver compartments. In the experi- mental model, a gamma counter placed over rat livers detects over time the concentrations of radiotracers. The review summarises the effects of liver temperature, hepatic perfusion, and canalicular transporter deficiency on Gd-BOPTA hepa- tocyte concentrations. A clinical study by Lukas Haider and colleagues investigates whether the evolution of liver functions can be predicted in patients with advanced liver fibrosis after hepatitis C virus eradication. They show that liver MRI fol- lowing the injection of Gd-EOB-DTPA may distinguish pa- tients with high or low risk of liver decompensation. Such prediction might initiate an individualised surveillance strategy.
Four publications examine the pharmacokinetics of PET radiotracers in rodents. Marco Taddio and colleagues de- scribe the pharmacokinetic modelling of new PET radio- tracers in mice and evidence how transporter inhibition by cyclosporine decreases their liver clearance while increasing the renal clearance. In rats, Fabien Caill´e and colleagues describe the labelling of metoclopramide and show that its transporter-mediated plasma clearance into hepatocytes is saturable and not modified by the P-glycoprotein inhibitor tariquidar. The P-glycoprotein canalicular transport of metoclopramide is inhibited by tariquidar which controls its
Hindawi
Contrast Media & Molecular Imaging Volume 2018, Article ID 2487405, 2 pages https://doi.org/10.1155/2018/2487405
liver exposure. Besides metabolism, this study highlights the role of hepatocyte transporters in the disposition of meto- clopramide in rat livers. Given the increased interest in bile acid PET imaging to assess the transport function of livers, Stef De Lombaerde and colleagues explorein vitrothe best
18F-labelled bile acids that are substrates of bile acid transporters. In mice, they show how these labelled bile acids can serve as PET biomarkers to analyse the hepatobiliary transport of bile acids. Andrea Testa and colleagues dem- onstrate the interactions of transporter inhibitors on the bile acid analogue [18F]LCATD transport across hepatocytes and suggest to use it in the early stage of drug development.
In summary, this special issue highlights the transport of several hepatobiliary contrast agents and radiotracers across hepatocytes. The transport across organic anion trans- porting polypeptide and multiple resistance-associated protein 2 is evidenced by the MR contrast agents Gd- BOPTA and Gd-EOB-DTPA. New labelled bile acids ex- plore the transport across the Na+-dependent taurocholate cotransporting polypeptide and the canalicular bile salt export pump. Other transporters such as P-glycoprotein are involved in the hepatocyte transport of drugs. These transports are studied in normal livers and livers with chronic disease. The main relevant topics of the issue focus on the hepatocyte concentrations induced by these transport functions and the transporter-mediated drug-drug in- teractions. Readers interested by the research topic can find more information on the website of the Hepatocyte Transporter Network led by Catherine Pastor (https://www.
unige.ch/hepatocyte-transporter-network/home/).
Conflicts of Interest
The editors declare that they have no conflicts of interest regarding the publication of this special issue.
Catherine M. Pastor Oliver Langer Bernard E. Van Beers
2 Contrast Media & Molecular Imaging
Stem Cells International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATIONof
Endocrinology
International Journal ofHindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed
Research International
Oncology
Journal ofHindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi www.hindawi.com
The Scientific World Journal
Volume 2018
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal ofHindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Computational and Mathematical Methods in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural Neurology Ophthalmology
Journal ofHindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal ofHindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s Disease
Evidence-Based Complementary and Alternative Medicine
Volume 2018 Hindawi
www.hindawi.com